Gene · 5921
NIH grants2,330
NIH grants whose papers are about the gene, through NIH's grant-paper links.
381 to 400 of 2,330
Download this page as JSON| Grant | Title | RASA1 papers | Newest fiscal year |
|---|---|---|---|
| R21AR083066 | Generation and Validation of Disease Models for Port-Wine Birthmarks | 1 | 2024 |
| R21MH131740 | Molecular analysis of glutamatergic neurons derived from iPSCs containing PPM1D truncating mutations found in Jansen de Vries Syndrome | 1 | 2024 |
| R25GM066567 | Tufts Post-Baccalaureate Research Education Program | 1 | 2024 |
| R25GM089569 | UNC PREP in the Biomedical Sciences | 1 | 2024 |
| R35CA231998 | Integrating genomics and the protein interactome for HPV+ head and neck cancer therapy | 1 | 2024 |
| R35CA232097 | Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance | 1 | 2024 |
| R35NS097211 | Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity | 1 | 2024 |
| R61AI169659 | Targeting HIV-1 RNA modifications in latently infected CD4+ T cells for therapeutic development | 1 | 2024 |
| T32CA251007 | UC Davis Comparative Oncology Training Program | 1 | 2024 |
| T32GM007863 | Michigan Medical Scientist Training Program | 1 | 2024 |
| T32GM008444 | Medical Scientist Training Program | 1 | 2024 |
| T32HS000063 | Training in Child Health Services Research and Implementation Science | 1 | 2024 |
| U01CA244314 | Human CD3epsilon co-potentiation to boost immunotherapy | 1 | 2024 |
| U19AI067773 | Center for High-Throughput Minimally-Invasive Radiation Biodosimetry | 1 | 2024 |
| UL1TR001430 | Boston University Clinical and Translational Science Institute | 1 | 2024 |
| UL1TR001449 | UNM HSC Clinical and Translational Science Center | 1 | 2024 |
| U54NS065705 | Brain Vascular Malformation Consortium: Predictor's of Clinical Course | 8 | 2023 |
| R01HL146352 | Molecular pathogenetic mechanisms in CM-AVM | 6 | 2023 |
| P50CA127003 | Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer | 3 | 2023 |
| R01CA234349 | Unraveling mechanisms of tumor suppression in lung cancer | 3 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5921/grants?page=20